Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.
List, Alan; Wei, Sheng; and McLaughlin, Mark L., "TLR9 targeted therapeutics" (2021). USF Patents. 1262.
H. Lee Moffitt Cancer Center and Research Institute, Inc.